PEDIATRICS Vol. 95 No. 2 February 1995, pp. 319-320
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wald, E. R.
Right arrow Articles by Dashefsky, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wald, E. R.
Right arrow Articles by Dashefsky, B.

Letters to the Editor

Ellen R. Wald MD1 and Barry Dashefsky MD2

1 University of Pittsburgh School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Diseases, Children's Hospital of Pittsburgh, Pittsburgh, PA 15213-2583
2 University of Pittsburgh School of Medicine, Divisions of Pediatric Infectious Diseases and General Academic Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA 15213-2583

We appreciate the support offered in the letter by Drs Mitchell, Newth, and Joffe. We are hopeful that continued questioning of the recently published guidelines on the use of ribavirin for respiratory syncytial virus infection will lead to a change in the recommendations.